TrialAnnals of hematology2026

Burixafor, a CXCR4 inhibitor with a differentiated kinetics profile: results of a phase 2 study for rapid cell mobilization in multiple myeloma and lymphoma patients undergoing transplant.

Devki D Sukhtankar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.